ReviewMarine drugs2019
Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies.
Review in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 3 syntheses or guidelines pooled it, 457 citations in OpenAlex.
- Exploring Marine-Derived Polysaccharides Through In Vitro and Zebrafish In Vivo Assays: Initial Trends of A Novel Approach to Drug Screening.Marine biotechnology (New York, N.Y.) · 2025Pooled it
- Fucoidan as a Promising Drug for Pain Treatment: Systematic Review and Meta-Analysis.Marine drugs · 2024Pooled it
- Therapeutic Effect of Natural Products and Dietary Supplements on Aflatoxin-Induced Nephropathy.International journal of molecular sciences · 2024Pooled it
- PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.GeroScience · 2026Article
- Disruption or partitioning? Deep eutectic solvent biphasic systems for integrated seaweed biorefineries.Bioresources and bioprocessing · 2026Article
- Article
- Fucoidan from Fucus Vesiculosus Alleviates Interstitial Cystitis by Suppressing the AKT/NLRP3 Inflammasome Axis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Tropical Seaweeds as a Sustainable Resource Towards Circular Bioeconomy: Insights and Way Forward.Molecular biotechnology · 2026Review
- Degraded sulfated galactan derived fromMolecular medicine reports · 2026Article
- Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation.International journal of molecular sciences · 2026Review
- Fucoidan Oligosaccharides fromMarine drugs · 2026Article
- Lysosomal vulnerability as a therapeutic target in thyroid cancer using fucoidan nanoparticles.Scientific reports · 2026Article
- Structure-Function Correlations of Commercial Fucoidan Extracts: Antioxidant, Antiviral, Antifungal, Antibacterial and Prebiotic Activities.Molecules (Basel, Switzerland) · 2026Article
- Fucoidan: An Update on Function, Role in Human Health and Applications.Chemical biology & drug design · 2026Review
- Signaling Pathways Triggering Therapeutical Potential of Marine-Derived Polysaccharides in Alzheimer's Disease: A Recent Review.Molecular neurobiology · 2026Review
- Marine Bioactives in Liver Aging: Mechanistic Insights and Translational Potential.Marine drugs · 2026Review
- Marine sulfated glycan inhibits tau-heparan sulfate interaction and tau cellular uptake.International journal of biological macromolecules · 2026Article
- Extraction and Optimization of Fucoidan From Sargassum muticum Using Acidic Eutectic Solvents and Evaluation of Their Effects on Fibroblast Cell Lines.ChemistryOpen · 2026Article
- Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia.Biomedicines · 2026Review
- Fucoidan fromMarine drugs · 2026Article
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The marine acid polysaccharide fucoidan has attracted attention from both the food and pharmaceutical industries due to its promising therapeutic effects. Fucoidan is a polysaccharide that mainly consists of L-fucose and sulphate groups. Its excellent biological function is attributed to its unique biological structure. Classical activities include antitumor, antioxidant, anticoagulant, antithrombotic, immunoregulatory, antiviral and anti-inflammatory effects. More recently, fucoidan has been shown to alleviate metabolic syndrome, protect the gastrointestinal tract, benefit angiogenesis and bone health. This review focuses on the progress in our understanding of the biological activities of fucoidan, highlighting its benefits for the treatment of human disease. We hope that this review can provide some theoretical basis and inspiration for the product development of fucoidan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.